CN119487027A - 作为parp1抑制剂的化合物 - Google Patents
作为parp1抑制剂的化合物 Download PDFInfo
- Publication number
- CN119487027A CN119487027A CN202380050136.0A CN202380050136A CN119487027A CN 119487027 A CN119487027 A CN 119487027A CN 202380050136 A CN202380050136 A CN 202380050136A CN 119487027 A CN119487027 A CN 119487027A
- Authority
- CN
- China
- Prior art keywords
- compound
- alkyl
- cancer
- ethyl
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2022/089986 | 2022-04-28 | ||
| CN2022089986 | 2022-04-28 | ||
| PCT/CN2023/077272 WO2023207283A1 (en) | 2022-04-28 | 2023-02-20 | Compounds as parp1 inhibitiors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN119487027A true CN119487027A (zh) | 2025-02-18 |
Family
ID=88517229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202380050136.0A Pending CN119487027A (zh) | 2022-04-28 | 2023-02-20 | 作为parp1抑制剂的化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250289814A1 (https=) |
| EP (1) | EP4514795A4 (https=) |
| JP (1) | JP2025517106A (https=) |
| KR (1) | KR20250033148A (https=) |
| CN (1) | CN119487027A (https=) |
| WO (1) | WO2023207283A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2023209820B2 (en) | 2022-01-21 | 2024-10-10 | Xinthera, Inc. | Parp1 inhibitors and uses thereof |
| KR20240161147A (ko) | 2022-03-14 | 2024-11-12 | 슬랩 파마슈티컬스 엘엘씨 | 다중 사이클릭 화합물 |
| FI4497438T3 (fi) | 2022-04-28 | 2025-10-20 | Xinthera Inc | Trisyklisiä parp1:n estäjiä ja niiden käyttötapoja |
| TW202416977A (zh) * | 2022-09-30 | 2024-05-01 | 大陸商中國醫藥研究開發中心有限公司 | 含氮雜環類化合物及其醫藥用途 |
| US20250129051A1 (en) * | 2023-10-23 | 2025-04-24 | Gilead Sciences, Inc. | Parp1 inhibitors and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP9903758A3 (en) * | 1996-05-29 | 2000-07-28 | Warner Lambert Co | Benzoxazinone dopamine d4 receptor antagonists and pharmaceutical compositions containing the same |
| GB0227240D0 (en) * | 2002-11-21 | 2002-12-31 | Glaxo Group Ltd | Compounds |
| RU2007101544A (ru) * | 2004-06-17 | 2008-08-10 | Уайт (Us) | Антагонисты рецепторов высвобождающего гонадотропин гормона |
| US8404713B2 (en) * | 2007-10-26 | 2013-03-26 | Janssen Pharmaceutica Nv | Quinolinone derivatives as PARP inhibitors |
| AR070221A1 (es) * | 2008-01-23 | 2010-03-25 | Astrazeneca Ab | Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas. |
| WO2010111626A2 (en) * | 2009-03-27 | 2010-09-30 | Takeda Pharmaceutical Company Limited | Poly (adp-ribose) polymerase (parp) inhibitors |
| MX2022000711A (es) * | 2019-07-19 | 2022-02-23 | Astrazeneca Ab | Inhibidores de parp1. |
| TW202309025A (zh) * | 2021-04-19 | 2023-03-01 | 美商辛瑟拉股份有限公司 | Parp1抑制劑及其用途 |
| WO2022228387A1 (en) * | 2021-04-26 | 2022-11-03 | Fochon Biosciences, Ltd. | Compounds as parp inhibitors |
| US20230159525A1 (en) * | 2021-10-01 | 2023-05-25 | Xinthera, Inc. | Azetidine and pyrrolidine parp1 inhibitors and uses thereof |
| TW202416977A (zh) * | 2022-09-30 | 2024-05-01 | 大陸商中國醫藥研究開發中心有限公司 | 含氮雜環類化合物及其醫藥用途 |
-
2023
- 2023-02-20 EP EP23794719.7A patent/EP4514795A4/en active Pending
- 2023-02-20 JP JP2024563976A patent/JP2025517106A/ja active Pending
- 2023-02-20 KR KR1020247039613A patent/KR20250033148A/ko active Pending
- 2023-02-20 WO PCT/CN2023/077272 patent/WO2023207283A1/en not_active Ceased
- 2023-02-20 CN CN202380050136.0A patent/CN119487027A/zh active Pending
- 2023-02-20 US US18/861,016 patent/US20250289814A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4514795A1 (en) | 2025-03-05 |
| JP2025517106A (ja) | 2025-06-03 |
| US20250289814A1 (en) | 2025-09-18 |
| KR20250033148A (ko) | 2025-03-07 |
| EP4514795A4 (en) | 2025-12-31 |
| WO2023207283A1 (en) | 2023-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11591331B2 (en) | PARP1 inhibitors and uses thereof | |
| CN119487027A (zh) | 作为parp1抑制剂的化合物 | |
| CA3214900A1 (en) | Carboxamide pyrolopyrazine and pyridine compounds useful as inhibitors of myt1 and use thereof in the treatment of cancer | |
| US12421241B2 (en) | Substituted pyridines as PARP1 inhibitors | |
| WO2021073439A1 (zh) | 用于抑制shp2活性的吡嗪衍生物 | |
| JP7680619B2 (ja) | Ｐａｒｐ１阻害薬及びその使用 | |
| US20260098024A1 (en) | Parp1 inhibitors and uses thereof | |
| US20250171418A1 (en) | Parp1 inhibitors and uses thereof | |
| CN113166105B (zh) | 作为cdk-hdac双通路抑制剂的杂环化合物 | |
| WO2023207284A1 (en) | Piperazine derivatives as parp1 inhibitiors | |
| CN120265637A (zh) | 靶向p53突变体的化合物 | |
| EP4129994A1 (en) | Novel pyrimidine derivative, and composition for preventing or treating neurodegenerative diseases and cancer, comprising same | |
| KR102342803B1 (ko) | 신규한 피리미딘 유도체 및 이를 포함하는 신경퇴행성 질환 및 암의 예방 또는 치료용 조성물 | |
| AU2024284667A1 (en) | Pyrazolo-pyrimidinone compounds for use in methods of inhibiting wee1 a kinase | |
| HK40115093A (zh) | Parp1抑制剂及其用途 | |
| CN118574824A (zh) | Parp1抑制剂及其用途 | |
| CN120774899A (zh) | 吡唑酰胺类化合物及用途 | |
| CN116217578A (zh) | 一类抑制mTOR同时降解GSPT1蛋白的双功能化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |